Prevention and treatment of cancer-related infections Journal Article
| Authors: | Baden, L. R.; Bensinger, W.; Angarone, M.; Casper, C.; Dubberke, E. R.; Freifeld, A. G.; Garzon, R.; Greene, J. N.; Greer, J. P.; Ito, J. I.; Karp, J. E.; Kaul, D. R.; King, E.; Mackler, E.; Marr, K. A.; Montoya, J. G.; Morris-Engemann, A.; Pappas, P. G.; Rolston, K.; Segal, B.; Seo, S. K.; Swaminathan, S.; Naganuma, M.; Shead, D. A. |
| Article Title: | Prevention and treatment of cancer-related infections |
| Abstract: | Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; fludarabine; neutropenia; review; splenectomy; drug efficacy; drug safety; hepatitis b; nonhuman; antineoplastic agents; drug megadose; neoplasms; cd8+ t lymphocyte; unindexed drug; low drug dose; bortezomib; infection; nephrotoxicity; bone marrow suppression; mucosa inflammation; risk factors; evidence based practice; aciclovir; antifungal agent; steroid; herpes simplex; herpes zoster; pneumocystis pneumonia; practice guideline; hematopoietic stem cell transplantation; high risk patient; antiinfective agent; anti-bacterial agents; hematologic malignancy; cd4+ t lymphocyte; graft versus host reaction; allogeneic hematopoietic stem cell transplantation; consensus development; antivirus agent; cidofovir; virus infection; infection prevention; immunocompromised host; immunosuppressive treatment; environmental factor; cotrimoxazole; quinoline derived antiinfective agent; bacterial infection; bacterial infections; fluconazole; foscarnet; ganciclovir; cytomegalovirus infection; mycosis; posaconazole; voriconazole; antifungal agents; cytomegalovirus; infection risk; aspergillosis; lung aspergillosis; autologous hematopoietic stem cell transplantation; clofarabine; alemtuzumab; virus diseases; micafungin; immunosuppressive agent; risk management; virus reactivation; cladribine; antimicrobial therapy; lamivudine; antiviral therapy; antiviral agents; randomized controlled trial (topic); famciclovir; nelarabine; systemic mycosis; mycoses; valaciclovir; entecavir; tenofovir; pneumocystosis; amphotericin b; airborne particle; low risk population; adefovir; telbivudine; asplenia; invasive candidiasis; oropharynx candidiasis |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 10 |
| Issue: | 11 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2012-11-01 |
| Start Page: | 1412 |
| End Page: | 1445 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 23138169 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "Source: Scopus" |
